The M6a Methyltransferase METTL3 Drives Neuroinflammation and Neurotoxicity Through Stabilizing BATF Mrna in Microglia
Xun Wu,Haixiao Liu,Jin Wang,Shenghao Zhang,Qing Hu,Tinghao Wang,Wenxing Cui,Yingwu Shi,Hao Bai,Jinpeng Zhou,Liying Han,Leiyang Li,Tianzhi Zhao,Yang Wu,Jianing Luo,Dayun Feng,Wei Guo,Shunnan Ge,Yan Qu
DOI: https://doi.org/10.1038/s41418-024-01329-y
IF: 12.067
2024-01-01
Cell Death and Differentiation
Abstract:Persistent neuroinflammation and progressive neuronal loss are defining features of acute brain injury including traumatic brain injury (TBI) and cerebral stroke. Microglia, the most abundant type of brain-resident immune cells, continuously surveil the environment and play a central role in shaping the inflammatory state of the central nervous system (CNS). In the study, we discovered that the protein expression of METTL3 (a m6A methyltransferase) was upregulated in inflammatory microglia independent of increased Mettl3 gene transcription following TBI in both human and mouse subjects. Subsequently, we identified TRIP12, a HECT-domain E3 ubiquitin ligase, as a negative regulator of METTL3 protein expression by facilitating METTL3 K48-linked polyubiquitination. Importantly, selective ablation of Mettl3 inhibited microglial pathogenic activities, diminished neutrophil infiltration, rescued neuronal loss and facilitated functional recovery post-TBI. Using MeRIP-seq and CUT&Tag sequencing, we identified that METTL3 promoted the expression of Basic Leucine Zipper Transcriptional Factor ATF-Like (BATF), which in turn directly bound to a cohort of characteristic inflammatory cytokines and chemokine genes. Enhanced activities of BATF in microglia elicited TNF-dependent neurotoxicity and can also promote neutrophil recruitment through releasing CXCL2. Pharmacological inhibition of METTL3 using a BBB-penetrating drug-loaded nano-system showed satisfactory therapeutic effects in both TBI and stroke mouse models. Collectively, our findings identified METTL3-m6A-BATF axis as a potential therapeutic target for terminating detrimental neuroinflammation and progressive neuronal loss following acute brain injury.